Fig. 1
From: ATG4B and pS383/392-ATG4B serve as potential biomarkers and therapeutic targets of colorectal cancer
The association of ATG4B and phosphorylated ATG4B with overall survival and DFS in patients with CRC. (A) Gene expression levels of ATG4B in tumor and adjacent normal tissues were obtained from TCGA and expressed as Reads Per Kilobase per Million (RPKM). * p < 0.05 vs. adjacent normal tissues. (B) The ATG4B expression was divided into high and low groups according to receiver operating characteristic curve (ROC). The association of ATG4B expression with overall, disease-free and progression-free survival was analyzed by Kaplan-Meier plots. (C) The scoring for protein levels of ATG4B and its phosphorylated form (p-ATG4B) was determined according to staining intensity of immunohistochemistry as representative images. Scale bar: 200 μm. (D) Kaplan-Meier plots were used to analyze the correlation of ATG4B or (E) phosphorylated ATG4B (p-ATG4B) with overall survival of CRC patients. (F) Kaplan-Meier analysis was used to evaluate to the correlation of ATG4B or (G) phosphorylated ATG4B (p-ATG4B) with DFS of CRC patients was examined. (H) The correlation of ATG4B and p-ATG4B was analyzed by Pearson X2 test